Anebulo Pharmaceuticals (ANEB) is a pre-revenue clinical-stage pharma company with a balance sheet dominated by cash and minimal tangible assets. Under a liquidation lens at December 31, 2025, the recovery posture is modestly positive but thin. Total assets are $9.4 million, of which $9.0 million is cash (100% recovery = $9.0 million), $0.18 million is prepaid expenses (negligible recovery at liquidation; effectively zero), $0.15 million is a NIDA grant receivable (probable collection, ~90-95% recovery = ~$0.14 million), and $0.15 million is other non-current assets consisting of unamortized loan commitment fees (zero recovery — pure intangible/deferred charge). No inventory, no PP&E, no goodwill. Adjusted liquidation asset value is approximately $9.1 million. Total liabilities at face value are $1.49 million, comprising accounts payable of $0.55 million and accrued liabilities of $0.93 million — both current, both face-value claims. No funded debt outstanding; the Loan Agreement (max $3.0 million, 0.25% per annum, matures February 2028) carries a zero drawn balance. Net liquidation recovery to equity is approximately $7.6 million, or roughly $0.19 per share on 41.1 million shares outstanding. The MFFAIS CLV/LLV/OLV of $8.1 million is consistent with this estimate, the slight difference attributable to haircut assumptions on non-cash current assets. The key change since the prior filing (Q1 FY2026, September 30, 2025) is a $1.4 million cash reduction ($10.4 million at September 30, 2025 to $9.0 million at December 31, 2025), driven by $2.6 million in operating cash burn partially offset by $0.6 million in NIDA grant receipts. Accrued liabilities jumped from $0.26 million to $0.93 million quarter-over-quarter, primarily from accrued executive bonuses and accrued R&D activity, shifting net working capital modestly downward. The accumulated deficit deepened from $76.0 million to $78.0 million. A material subsequent event affects forward recovery: the company completed a $1.05 million tender offer in January 2026 (300,000 shares at $3.50) and notified Nasdaq of voluntary delisting on February 6, 2026, with Form 25 and Form 15 filings expected ~February 27, 2026. This going-private process will reduce cash by approximately $1.1 million (including fees) from the December 31, 2025 balance. No outstanding CRO contract obligation (~$3.5 million total, substantially unincurred) and CMO stability study (~$3.0 million total, stability phase pending in calendar 2026) represent off-balance-sheet commitments not captured in accrued liabilities; these do not appear as XBRL-tagged liabilities and would be cancellable in a wind-down scenario per contract terms disclosed in MD&A. The Vernalis license carries up to $29.9 million in development milestones but none are currently probable and no liability is recorded — correctly treated as contingent and non-accrued.
▼ Community Notes